FOLH1 and prostate carcinoma: Prostate specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with α- or β-particle emitting radionuclides have shown extraordinary efficacy in the treatment of end-stage prostate cancer in patients who have exhausted all approved options [1].